Navigation Links
Second Quarter Health Care M&A Strongest In Years According To New Report From Irving Levin Associates, Inc.
Date:7/9/2008

NORWALK, Conn., July 9 /PRNewswire/ -- According to a new Report from Irving Levin Associates, a total of 265 mergers and acquisitions were announced in the health care industry during the second quarter of 2008, a 19% increase from the 223 deals announced in the prior quarter. Based on preliminary figures, a total of $85.5 billion was committed to fund the second quarter's M&A activity, a 209% increase over the prior quarter's $27.7 billion. It is also a 25% increase over the $68.3 billion spent in Q2:06 and a 39% increase over the $61.3 billion spent in Q2:07. Despite the slow-down in global M&A, activity in the health care industry is robust and on the rise.

The Health Care M&A Market Second Quarter 2008

Dollar Amounts By Sector*

Dollar Amount Percent of

Second Quarter Quarter

Sector 2008

Home Health Care $1,658,700,000 2 %

Hospitals 644,000,000 <1 %

Long-Term Care 361,750,000 <1 %

Labs, MRI, Dialysis 29,587,000 <1 %

Managed Care 14,500,000 <1 %

Rehabilitation 9,500,000 <1 %

Behavioral Health Care 0 -

Physician Medical Groups 0 -

Other Services 2,118,558,000 3 %

Services subtotal $4,807,008,000 6 %

Medical Devices $53,347,291,000 63 %

Biotechnology 16,316,388,000 19 %

Pharmaceuticals 8,207,938,000 9 %

e-Health 2,817,300,000 3 %

Technology subtotal $80,688,917,000 94 %

Total health care $85,495,925,000 100 %

*Preliminary figures

The health care technology segment attracted the largest amount of capital, capturing nearly 95 cents out of every dollar invested in health care M&A. This portion is up from the first quarter when 80 cents out of every health care M&A dollar was spent in the technology sectors.

The number of deals announced in each sector of the health care industry appears in the chart below, along with comparisons to the prior quarter (Q1:08) and the year-ago quarter (Q2:07).

The Health Care M&A Market Q2:08 - Deal Volume By Sector

Q2:08 Q1:08 % Q2:07 %

Sector Deals* Deals Change Deals Change

Services Segment:

Long-Term Care 21 28 -25% 27 -22%

Physician Groups 12 12 0% 6 100%

Home Health Care 13 11 18% 18 -28%

Hospitals 12 10 20% 15 -20%

Labs, MRI, Dialysis 8 10 -20% 12 -33%

Managed Care 3 7 -57% 9 -67%

Rehabilitation 4 6 -33% 4 0%

Behavioral Health

Care 3 3 0% 3 0%

Other 34 23 48% 27 26%

Services Subtotal 110 110 0% 121 -9%

Technology Segment:

Medical Devices 51 35 46% 40 28%

Pharmaceuticals 38 34 12% 39 -3%

Biotechnology 46 29 59% 37 24%

e-Health 20 15 33% 15 33%

Technology Subtotal 155 113 37% 131 18%

Grand Total 265 223 19% 252 5%

*Preliminary figures

These results point to a resurgence of interest in health care M&A despite a lackluster start at the beginning of the year. "After a lethargic first quarter, both deal and dollar volume in the health care M&A market surged in the second," stated Sanford Steever, Ph.D., editor of The Health Care M&A Report. "Given the relative absence of financial buyers from the market, a greater number of strategic buyers now feel more confident in entering the market," added Mr. Steever.

The Health Care industry continues to attract more interest from potential deal makers than other sectors of the economy. "The combination of health care and technology is proving irresistible for investors and operators looking to enter the M&A market," commented Stephen M. Monroe, managing editor at Irving Levin Associates. "While sectors such as Medical Devices and Biotechnology are obvious magnets for M&A dollars, so too are technologically-oriented services sectors such as Infusion Therapy and Contract Research Organizations."

"Though not completely insulated from the surrounding economy and its influence, the health care M&A market appears to run on an internal logic of its own and to have access to sufficient capital to make it happen," Mr. Steever summarized. "Deals in health care technology will likely drive the market for the remainder of the year."

For more information on The Health Care M&A Report, or for a subscription to any Irving Levin publications, call 800-248-1668. Irving Levin Associates, Inc., established in 1948, has headquarters in Norwalk, CT and is online at http://www.levinassociates.com. This privately held corporation publishes research reports and newsletters, and maintains merger and acquisition and venture capital databases, on the health care and senior housing markets.


'/>"/>
SOURCE Irving Levin Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Response Genetics Reports Second Quarter 2007 Financial Results
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Transgenomic, Inc. Reports Second Quarter 2007 Results
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today ... peptide drug candidates, PTG-100 and PTG-200, at the ... and Colitis Organization (ECCO).  The ECCO congress is ... from February 15 – 18, 2017. ... Protagonist drug candidates PTG-100 and PTG-200. PTG-100, a ...
(Date:2/16/2017)... 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... a better treatment for triple negative breast cancer (TNBC), announced ... France program. The YEi Start in ... to help entrepreneurs grow their business in France ... American companies selected to complete an intensive one week immersion ...
(Date:2/16/2017)... Feb. 16, 2017  ArmaGen, Inc., a privately ... to treat severe neurological disorders, today reported preliminary ... AGT-181, the company,s investigational therapy for the treatment ... mucopolysaccharidosis type I, or MPS I). The initial ... study, presented today at the 13 th ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
Breaking Biology News(10 mins):